Announcements Trials
Browse Landscape

Status

No longer available 4Approved for marketing 2Available 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 394Observational 130Expanded_access 7

Sponsor

Cancer Type

NET 7Endocrine 7Sarcoma 1

Conditions

Neoplasms 37Carcinoma, Non-Small-Cell Lung 34Multiple Myeloma 32Recurrence 29Prostatic Neoplasms 28Melanoma 21Leukemia, Myeloid, Acute 21Breast Neoplasms 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Glioblastoma 15Pancreatic Neoplasms 14Sarcoma 13Neuroblastoma 13Lymphoma 13Glioma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia 10Ovarian Neoplasms 9Lung Neoplasms 9Colorectal Neoplasms 9Carcinoma, Hepatocellular 9Small Cell Lung Carcinoma 8Lymphoma, Large B-Cell, Diffuse 8Lambert-Eaton Myasthenic Syndrome 8Pheochromocytoma 7Neuroendocrine Tumors 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Gastrointestinal Stromal Tumors 7Carcinoma, Renal Cell 7

Interventions

Ga(III)-DOTATOC 2surufatinib 1lutetium Lu 177 dotatate 1Gallium-68 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Expanded_access × Neuroendocrine Tumors × Clear all
NCT07262970 2025-12-04

Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

Rezolute

Available
EndocrineNETSarcoma

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT04814732 2024-04-12

Expanded Access Program of Surufatinib

Hutchmed

No longer available
EndocrineNET

Neuroendocrine Tumors

NCT04334837 2020-10-09

Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)

Curium US LLC

Approved for marketing
EndocrineNET

Neuroendocrine Tumors

NCT02174679 2020-07-27

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

Jonsson Comprehensive Cancer Center

No longer available
EndocrineNET

Carcinoma, Medullary, Neuroendocrine Tumors

NCT02705313 2018-04-09

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

Advanced Accelerator Applications

Approved for marketing
EndocrineNET

Neuroendocrine Tumors

NCT02375464 2016-11-08

Gallium-68 DOTATOC for Management of Neuroendocrine Tumors

Northwell Health

No longer available
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT02358018 2016-11-02

68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial

Memorial Sloan Kettering Cancer Center

No longer available
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡